Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.
Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.
[Differential diagnosis between multiple sclerosis and neurological presentations of HIV-infection: a literature review and a case report].
A patient with both narcolepsy and multiple sclerosis in association with Pandemrix vaccination.
Pitfalls of 3D FLAIR Brain Imaging: A Prospective Comparison with 2D FLAIR.
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.
Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis.
PERK Dependent Activation of JAK1 and STAT3 Contributes to ER Stress Induced Inflammation.
[Quality of life of patients receiving long-term treatment with first-line disease-modifying drugs: results of a Russian multicenter study using MusiQoL.]
Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study.
Cognitive deficit is related to immune-cell beta-NGF in multiple sclerosis patients.
Protein tyrosine phosphatase receptor type z negatively regulates oligodendrocyte differentiation and myelination.
Lack of response to rituximab therapy in patients with neuromyelitis optica: True non-responders or insufficient treatment?
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis.
Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease.
Multiple sclerosis, blood flow, and CSF circulation.
On the Epidemiology of Multiple Sclerosis in the Middle East and North Africa.
B-cell enrichment and epstein-barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis.
Higher burden of migraine compared to other neurological conditions: results from a cross-sectional study.
Managed care aspects of managing multiple sclerosis.
Associated with intrathecal baclofen treatment and duloxetine in patients with multiple sclerosis.
Reverse causality behind the association between reproductive history and MS.
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
Multiple sclerosis: genetics, biomarkers, treatments.
Pages
« first
‹ previous
…
223
224
225
226
227
228
229
230
231
…
next ›
last »